{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:00:15Z","timestamp":1785895215701,"version":"3.56.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>There are multiple obstacles encountered by immigrants attempting to engage hepatitis C virus (HCV) care and treatment. We evaluated the diversity and treatment outcomes of HCV-infected immigrants evaluated for Direct Acting Antiviral (DAA) therapy in Canada.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The Canadian Network Undertaking against Hepatitis C (CANUHC) Cohort contains demographic information and DAA treatment information prospectively collected at 10 Canadian sites. Information on country of origin and race are collected. Characteristics and outcomes (sustained virological response; SVR) were compared by immigration status and race.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Between January 2016 and May 2018, 725 HCV-infected patients assessed for DAA therapy were enrolled in CANUHC (mean age: 52.66\u2009\u00b1\u200912.68\u2009years); 65.66% male; 82.08% White, 5.28% Indigenous, 4.64% South East Asian, 4.64% East Indian, 3.36% Black). 18.48% were born outside of Canada. Mean age was similar [immigrants: 54.36\u2009\u00b1\u200913.95\u2009years), Canadian-born: 52.27\u2009\u00b1\u200912.35\u2009years); (<jats:italic>p<\/jats:italic>\u2009=\u20090.085)]. The overall baseline fibrosis score (in kPa measured by transient elastography) was similar among Canadian and foreign-born patients. Fibrosis score was not predicted by race or genotype. The proportion initiating DAA therapy was similar by immigrant status (56.72% vs 49.92%). SVR rates by intent-to-treat analysis were similar (immigrants-89.47%, Canadian-born-92.52%; <jats:italic>p<\/jats:italic>\u2009=\u20090.575).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>A diverse immigrant population is engaging care in Canada, initiating HCV antiviral therapy in an equitable fashion and achieving SVR proportions similar to Canada-born patients. Our Canadian experience may be of value in informing HCV elimination efforts in economically developed regions.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12889-020-09464-0","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T08:03:43Z","timestamp":1599120223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-3499","authenticated-orcid":false,"given":"Curtis L.","family":"Cooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Vachon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alnoor","family":"Ramji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Borgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the CANUHC Cohort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"9464_CR1","unstructured":"World Health Organization. Global hepatitis report. Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/255016\/1\/9789241565455-eng.pdf?ua=1. Accessed 19 June."},{"issue":"9","key":"9464_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637\u201348.","journal-title":"Ann Intern Med"},{"issue":"5","key":"9464_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1155\/2014\/317623","volume":"28","author":"RP Myers","year":"2014","unstructured":"Myers RP, Krajden M, Bilodeau M, et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol. 2014;28(5):243\u201350.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"19","key":"9464_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.14745\/ccdr.v40i19a02","volume":"40","author":"M Trubnikov","year":"2014","unstructured":"Trubnikov M, Yan P, Archibald C. Estimated prevalence of hepatitis C virus infection in Canada, 2011. Can Commun Dis Rep. 2014;40(19):429\u201336.","journal-title":"Can Commun Dis Rep"},{"key":"9464_CR5","unstructured":"Canada S. Immigration and ethnocultural diversity: Key results from the 2016 Census. Available at: https:\/\/www150.statcan.gc.ca\/n1\/en\/daily-quotidien\/171025\/dq171025b-eng.pdf?st=pGwPtyaM. Accessed 1 June."},{"issue":"1","key":"9464_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12879-017-2242-y","volume":"17","author":"C Greenaway","year":"2017","unstructured":"Greenaway C, Azoulay L, Allard R, et al. A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada. BMC Infect Dis. 2017;17(1):140.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"9464_CR7","doi-asserted-by":"publisher","first-page":"e82440","DOI":"10.1371\/journal.pone.0082440","volume":"8","author":"B Abarca Tomas","year":"2013","unstructured":"Abarca Tomas B, Pell C, Bueno Cavanillas A, Guillen Solvas J, Pool R, Roura M. Tuberculosis in migrant populations. A systematic review of the qualitative literature. PLoS One. 2013;8(12):e82440.","journal-title":"PLoS One"},{"issue":"6","key":"9464_CR8","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1007\/s10903-015-0276-z","volume":"18","author":"S Ahmed","year":"2016","unstructured":"Ahmed S, Shommu NS, Rumana N, Barron GR, Wicklum S, Turin TC. Barriers to access of primary healthcare by immigrant populations in Canada: a literature review. J Immigr Minor Health. 2016;18(6):1522\u201340.","journal-title":"J Immigr Minor Health"},{"issue":"8","key":"9464_CR9","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1365-2893.2012.01583.x","volume":"19","author":"W Chen","year":"2012","unstructured":"Chen W, Tomlinson G, Krahn M, Heathcote J. Immigrant patients with chronic hepatitis C and advanced fibrosis have a higher risk of hepatocellular carcinoma. J Viral Hepat. 2012;19(8):574\u201380.","journal-title":"J Viral Hepat"},{"issue":"11","key":"9464_CR10","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/cid\/ciw540","volume":"63","author":"R Kamstra","year":"2016","unstructured":"Kamstra R, Azoulay L, Steele R, Klein MB, Greenaway C. Hospitalizations in immigrants and nonimmigrants diagnosed with chronic hepatitis C infection in Quebec. Clin Infect Dis. 2016;63(11):1439\u201348.","journal-title":"Clin Infect Dis"},{"key":"9464_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2296-13-128","volume":"13","author":"E Muggah","year":"2012","unstructured":"Muggah E, Dahrouge S, Hogg W. Access to primary health care for immigrants: results of a patient survey conducted in 137 primary care practices in Ontario, Canada. BMC Fam Pract. 2012;13:128.","journal-title":"BMC Fam Pract"},{"issue":"5","key":"9464_CR12","doi-asserted-by":"publisher","first-page":"720","DOI":"10.5604\/01.3001.0010.2714","volume":"16","author":"CL Cooper","year":"2017","unstructured":"Cooper CL, Thavorn K, Damian E, Corsi DJ. Hepatitis C virus infection outcomes among immigrants to Canada: a retrospective cohort analysis. Ann Hepatol. 2017;16(5):720\u20136.","journal-title":"Ann Hepatol"},{"issue":"9","key":"9464_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1097\/MEG.0b013e328326f598","volume":"21","author":"C Giordano","year":"2009","unstructured":"Giordano C, Druyts EF, Garber G, Cooper C. Evaluation of immigration status, race and language barriers on chronic hepatitis C virus infection management and treatment outcomes. Eur J Gastroenterol Hepatol. 2009;21(9):963\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"9464_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1478-3231.2011.02539.x","volume":"31","author":"M Cornberg","year":"2011","unstructured":"Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31(Suppl 2):30\u201360.","journal-title":"Liver Int"},{"issue":"Suppl 1","key":"9464_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","volume":"29","author":"D Lavanchy","year":"2009","unstructured":"Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74\u201381.","journal-title":"Liver Int"},{"issue":"6","key":"9464_CR16","doi-asserted-by":"publisher","first-page":"e99677","DOI":"10.1371\/journal.pone.0099677","volume":"9","author":"J Pepin","year":"2014","unstructured":"Pepin J, Abou Chakra CN, Pepin E, Nault V, Valiquette L. Evolution of the global burden of viral infections from unsafe medical injections, 2000-2010. PLoS One. 2014;9(6):e99677.","journal-title":"PLoS One"},{"issue":"7","key":"9464_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","volume":"16","author":"L Platt","year":"2016","unstructured":"Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797\u2013808.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"9464_CR18","doi-asserted-by":"publisher","first-page":"e0141715","DOI":"10.1371\/journal.pone.0141715","volume":"10","author":"C Greenaway","year":"2015","unstructured":"Greenaway C, Thu Ma A, Kloda LA, et al. The Seroprevalence of hepatitis C antibodies in immigrants and refugees from intermediate and high endemic countries: a systematic review and meta-analysis. PLoS One. 2015;10(11):e0141715.","journal-title":"PLoS One"},{"issue":"2","key":"9464_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3138\/canlivj.1.2.004","volume":"1","author":"C Greenaway","year":"2018","unstructured":"Greenaway C, Makarenko I, Tanveer F, Janjua NZ. Addressing hepatitis C in the foreign-born population: a key to hepatitis C virus elimination in Canada. Can Liver J. 2018;1(2):34\u201350.","journal-title":"Can Liver J"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-09464-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-020-09464-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-09464-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T08:33:36Z","timestamp":1630658016000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-09464-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9464"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-09464-0","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Canadian Network Undertaking against Hepatitis C (CANUHC) Cohort contains demographic and HCV DAA treatment information prospectively collected since January 2016 at 10 Canadian-based, publicly funding clinic sites at which patients are referred for HCV evaluation and antiviral treatment. Participants attending CANUHC sites and providing written informed consent are enrolled. Overall research ethics board approval for this cohort study was obtained by the Health Research Ethics Board of Alberta (HREBA)-Community Health Committee (CHC) [HREBA.CHC-16-0038_REN3] where the primary database is housed. Each individual contributing site has also obtained local research ethics board approval.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1345"}}